Evaluation of chemosensitivity prediction using quantitative dose-response curve classification for highly advanced/relapsed gastric cancer

World Journal of Surgical Oncology

Volumn 11, Issue , 2013, Pages

  Matsuo, Teppei ^a   Nishizuka, Satoshi S ^a   Ishida, Kazushige ^a   Endo, Fumitaka ^a   Katagiri, Hirokatsu ^a   Kume, Kohei ^a   Ikeda, Miyuki ^a   Koeda, Keisuke ^a   Wakabayashi, Go ^a  

^a IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

Ascites; Chemosensitivity; Dose response curves; Gastric cancer

Indexed keywords

CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FIRTECAN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; METHOTREXATE; OXALIPLATIN; PACLITAXEL; VINORELBINE DITARTRATE;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CARCINOMATOUS PERITONITIS; CHEMOSENSITIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MAXIMUM PLASMA CONCENTRATION; PREDICTION; QUANTITATIVE STUDY; STOMACH CANCER;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ASCITES; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; STOMACH NEOPLASMS; TUMOR CELLS, CULTURED; YOUNG ADULT;

EID: 84872441097     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-11-11     Document Type: Article

References (17)

1. Narahara H, Iishi H, Imamura H, Tsuburaya A, Chin K, Imamoto H, Esaki T, Furukawa H, Hamada C, Sakata Y. Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002). Gastric Cancer 2011, 14:72-80. 10.1007/s10120-011-0009-5, 3056989, 21340666.
2. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, Arai K. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007, 357:1810-1820. 10.1056/NEJMoa072252, 17978289.
3. Thuss-Patience PC, Kretzschmar A, Dogan Y, Rothmann F, Blau I, Schwaner I, Breithaupt K, Bichev D, Grothoff M, Grieser C, Reichardt P. Docetaxel and capecitabine for advanced gastric cancer: investigating dose-dependent efficacy in two patient cohorts. Br J Cancer 2011, 105:505-512. 10.1038/bjc.2011.278, 3170974, 21792201.
4. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001, 345:725-730. 10.1056/NEJMoa010187, 11547741.
5. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, MAGIC Trial Participants Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006, 355:11-20. 10.1056/NEJMoa055531, 16822992, MAGIC Trial Participants.
6. Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, Nashimoto A, Fujii M, Nakajima T, Ohashi Y. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 2011, 29:4387-4393. 10.1200/JCO.2011.36.5908, 22010012.
7. Nashimoto A, Nakajima T, Furukawa H, Kitamura M, Kinoshita T, Yamamura Y, Sasako M, Kunii Y, Motohashi H, Yamamoto S. Randomized trial of adjuvant chemotherapy with mitomycin, Fluorouracil, and Cytosine arabinoside followed by oral Fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206-1. J Clin Oncol 2003, 21:2282-2287. 10.1200/JCO.2003.06.103, 12805327.
8. Furukawa T, Kubota T, Watanabe M, Takahara T, Yamaguchi H, Takeuchi T, Kase S, Kodaira S, Ishibiki K, Kitajima M, et al. High in vitro-in vivo correlation of drug response using sponge-gel-supported three-dimensional histoculture and the MTT end point. Int J Cancer 1992, 51:489-498. 10.1002/ijc.2910510325, 1592540.
9. Hoffman RM. In vitro sensitivity assays in cancer: a review, analysis, and prognosis. J Clin Lab Anal 1991, 5:133-143. 10.1002/jcla.1860050211, 2023059.
10. Kawamura H, Ikeda K, Takiyama I, Terashima M. The usefulness of the ATP assay with serum-free culture for chemosensitivity testing of gastrointestinal cancer. Eur J Cancer 1997, 33:960-966. 10.1016/S0959-8049(97)00075-0, 9291821.
11. Kubota T, Sasano N, Abe O, Nakao I, Kawamura E, Saito T, Endo M, Kimura K, Demura H, Sasano H, et al. Potential of the histoculture drug-response assay to contribute to cancer patient survival. Clin Cancer Res 1995, 1:1537-1543.
12. Yoshimasu T, Oura S, Hirai I, Tamaki T, Kokawa Y, Ota F, Nakamura R, Shimizu Y, Kawago M, Hirai Y, Naito K, Kiyoi M, Tanino H, Okamura Y, Furukawa T. In vitro evaluation of dose-response curve for paclitaxel in breast cancer. Breast Cancer 2007, 14:401-405. 10.2325/jbcs.14.401, 17986806.
13. Arteaga CL, Forseth BJ, Clark GM, Von Hoff DD. A radiometric method for evaluation of chemotherapy sensitivity: results of screening a panel of human breast cancer cell lines. Cancer Res 1987, 47:6248-6253.
14. Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 2003, 3:502-516. 10.1038/nrc1123, 12835670.
15. Richter L, Ruckert U, Kramer S. Learning a predictive model for growth inhibition from the NCI DTP human tumor cell line screening data: does gene expression make a difference?. Pac Symp Biocomput 2006, 596-607.
16. Kim K, Chun KH, Suh PG, Kim IH. Alterations in cell proliferation related gene expressions in gastric cancer. Crit Rev Eukaryot Gene Expr 2011, 21:237-254. 10.1615/CritRevEukarGeneExpr.v21.i3.20, 22111712.
17. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H, Takeuchi M. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008, 9:215-221. 10.1016/S1470-2045(08)70035-4, 18282805.